Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 90

1.

Emphysema phenotypes and lung cancer risk.

González J, Henschke CI, Yankelevitz DF, Seijo LM, Reeves AP, Yip R, Xie Y, Chung M, Sánchez-Salcedo P, Alcaide AB, Campo A, Bertó J, Del Mar Ocón M, Pueyo J, Bastarrika G, de-Torres JP, Zulueta JJ.

PLoS One. 2019 Jul 25;14(7):e0219187. doi: 10.1371/journal.pone.0219187. eCollection 2019.

2.

Screening in Lung Cancer: The Latest Evidence.

Seijo LM, Trujillo JC, Zulueta JJ.

Arch Bronconeumol. 2019 Jun 13. pii: S0300-2896(19)30247-9. doi: 10.1016/j.arbres.2019.04.019. [Epub ahead of print] English, Spanish. No abstract available.

3.

The effect of radiographic emphysema in assessing lung cancer risk.

Yong PC, Sigel K, de-Torres JP, Mhango G, Kale M, Kong CY, Zulueta JJ, Wilson D, Brown SW, Slatore C, Wisnivesky J.

Thorax. 2019 Sep;74(9):858-864. doi: 10.1136/thoraxjnl-2018-212457. Epub 2019 Feb 5.

PMID:
30723183
4.

The Prevalence of Obstructive Lung Disease in a Lung Cancer Screening Cohort: Analysis of the National Lung Screening Trial-American College of Radiology Image Network Cohort.

de-Torres JP, Wisnivesky JP, Bastarrika G, Wilson DO, Celli BR, Zulueta JJ.

Ann Am Thorac Soc. 2019 May;16(5):641-644. doi: 10.1513/AnnalsATS.201811-817RL. No abstract available.

PMID:
30673510
5.

Radiologic features of small pulmonary nodules detected in initially negative screening CT examinations: a step towards personalized screening strategies?

Bastarrika G, de-Torres JP, Zulueta JJ.

Ann Transl Med. 2018 Nov;6(Suppl 1):S51. doi: 10.21037/atm.2018.10.14. No abstract available.

6.

Biomarkers in Lung Cancer Screening: Achievements, Promises, and Challenges.

Seijo LM, Peled N, Ajona D, Boeri M, Field JK, Sozzi G, Pio R, Zulueta JJ, Spira A, Massion PP, Mazzone PJ, Montuenga LM.

J Thorac Oncol. 2019 Mar;14(3):343-357. doi: 10.1016/j.jtho.2018.11.023. Epub 2018 Dec 4. Review.

PMID:
30529598
7.

At last we can go ahead with low-dose CT screening for lung cancer in Europe.

Veronesi G, Zulueta JJ, Maisonneuve P, Henschke C.

Lung Cancer. 2018 Sep;123:176-177. doi: 10.1016/j.lungcan.2018.07.010. Epub 2018 Jul 10. No abstract available.

PMID:
30017427
8.

Incorporating Coexisting Chronic Illness into Decisions about Patient Selection for Lung Cancer Screening. An Official American Thoracic Society Research Statement.

Rivera MP, Tanner NT, Silvestri GA, Detterbeck FC, Tammemägi MC, Young RP, Slatore CG, Caverly TJ, Boyd CM, Braithwaite D, Fathi JT, Gould MK, Iaccarino JM, Malkoski SP, Mazzone PJ, Tanoue LT, Schoenborn NL, Zulueta JJ, Wiener RS; American Thoracic Society Assembly on Thoracic Oncology.

Am J Respir Crit Care Med. 2018 Jul 15;198(2):e3-e13. doi: 10.1164/rccm.201805-0986ST.

PMID:
30004250
9.

A novel protein-based prognostic signature improves risk stratification to guide clinical management in early-stage lung adenocarcinoma patients.

Martínez-Terroba E, Behrens C, de Miguel FJ, Agorreta J, Monsó E, Millares L, Sainz C, Mesa-Guzman M, Pérez-Gracia JL, Lozano MD, Zulueta JJ, Pio R, Wistuba II, Montuenga LM, Pajares MJ.

J Pathol. 2018 Aug;245(4):421-432. doi: 10.1002/path.5096. Epub 2018 Jun 20.

10.

Pulmonary arterial enlargement predicts long-term survival in COPD patients.

de-Torres JP, Ezponda A, Alcaide AB, Campo A, Berto J, Gonzalez J, Zulueta JJ, Casanova C, Rodriguez-Delgado LE, Celli BR, Bastarrika G.

PLoS One. 2018 Apr 25;13(4):e0195640. doi: 10.1371/journal.pone.0195640. eCollection 2018.

11.

Chronic Obstructive Pulmonary Disease (COPD) as a disease of early aging: Evidence from the EpiChron Cohort.

Divo MJ, Celli BR, Poblador-Plou B, Calderón-Larrañaga A, de-Torres JP, Gimeno-Feliu LA, Bertó J, Zulueta JJ, Casanova C, Pinto-Plata VM, Cabrera-Lopez C, Polverino F, Carmona Píréz J, Prados-Torres A, Marin JM; EpiChron—BODE Collaborative Group.

PLoS One. 2018 Feb 22;13(2):e0193143. doi: 10.1371/journal.pone.0193143. eCollection 2018.

12.

Complement C4d-specific antibodies for the diagnosis of lung cancer.

Ajona D, Okrój M, Pajares MJ, Agorreta J, Lozano MD, Zulueta JJ, Verri C, Roz L, Sozzi G, Pastorino U, Massion PP, Montuenga LM, Blom AM, Pio R.

Oncotarget. 2017 Dec 26;9(5):6346-6355. doi: 10.18632/oncotarget.23690. eCollection 2018 Jan 19.

13.

Comparison of the 2017 and 2015 Global Initiative for Chronic Obstructive Lung Disease Reports. Impact on Grouping and Outcomes.

Cabrera López C, Casanova Macario C, Marín Trigo JM, de-Torres JP, Sicilia Torres R, González JM, Polverino F, Divo M, Pinto Plata V, Zulueta JJ, Celli B.

Am J Respir Crit Care Med. 2018 Feb 15;197(4):463-469. doi: 10.1164/rccm.201707-1363OC.

PMID:
29099607
14.

Prospective comparison of non-invasive risk markers of major cardiovascular events in COPD patients.

Zagaceta J, Bastarrika G, Zulueta JJ, Colina I, Alcaide AB, Campo A, Divo M, Casanova C, Marin JM, Pinto-Plata VM, Celli BR, de-Torres JP.

Respir Res. 2017 Sep 29;18(1):175. doi: 10.1186/s12931-017-0658-y.

15.

Understanding the Links Between Lung Cancer, COPD, and Emphysema: A Key to More Effective Treatment and Screening.

Seijo LM, Zulueta JJ.

Oncology (Williston Park). 2017 Feb 15;31(2):93-102. Review.

16.

Telomere length, COPD and emphysema as risk factors for lung cancer.

de-Torres JP, Sanchez-Salcedo P, Bastarrika G, Alcaide AB, Pío R, Pajares MJ, Campo A, Berto J, Montuenga L, Del Mar Ocon M, Monente C, Celli BR, Zulueta JJ.

Eur Respir J. 2017 Jan 3;49(1). pii: 1601521. doi: 10.1183/13993003.01521-2016. Print 2017 Jan. No abstract available.

17.

Clinical Features of Smokers With Radiological Emphysema But Without Airway Limitation.

Alcaide AB, Sanchez-Salcedo P, Bastarrika G, Campo A, Berto J, Ocon MD, Fernandez-Montero A, Celli BR, Zulueta JJ, de-Torres JP.

Chest. 2017 Feb;151(2):358-365. doi: 10.1016/j.chest.2016.10.044. Epub 2016 Nov 3.

PMID:
27818328
18.

[Lung cancer screening using low-dose computed tomography. In favour].

Bertó J, Zulueta JJ.

Gac Sanit. 2016 Sep-Oct;30(5):386-8. doi: 10.1016/j.gaceta.2016.07.001. Epub 2016 Jul 25. Spanish. No abstract available.

19.

Recommendations of the Spanish Society of Pneumology and Thoracic Surgery on the diagnosis and treatment of non-small-cell lung cancer.

Álvarez FV, Trueba IM, Sanchis JB, López-Rodó LM, Rodríguez Suárez PM, de Cos Escuín JS, Barreiro E, Henar Borrego Pintado M, Vicente CD, Aldeyturriaga JF, Gámez García P, Garrido López P, León Atance P, Izquierdo Elena JM, Novoa Valentín NM, Rivas de Andrés JJ, Crespo ÍR, Velázquez ÁS, Seijo Maceiras LM, Reina SS, Bujanda DA, Ávila Martínez RJ, de Granda Orive JI, Martínez Ede H, Gude VD, Flor RE, Freixinet Gilart JL, García Jiménez MD, Alarza FH, Sarmiento SH, Honguero Martínez AF, Jiménez Ruiz CA, Sanz IL, Mariscal de Alba A, Martínez Vallina P, Menal Muñoz P, Pérez LM, Olmedo García ME, Rombolá CA, Arregui ÍS, Somiedo Gutiérrez Mdel V, Triviño Ramírez AI, Trujillo Reyes JC, Vallejo C, Lozano PV, Simó GV, Zulueta JJ.

Arch Bronconeumol. 2016 May;52 Suppl 1:2-62. doi: 10.1016/S0300-2896(16)30198-3. English, Spanish. No abstract available.

20.

Executive summary of the SEPAR recommendations for the diagnosis and treatment of non-small cell lung cancer.

Villar Álvarez F, Muguruza Trueba I, Belda Sanchis J, Molins López-Rodó L, Rodríguez Suárez PM, Sánchez de Cos Escuín J, Barreiro E, Borrego Pintado MH, Disdier Vicente C, Flandes Aldeyturriaga J, Gámez García P, Garrido López P, León Atance P, Izquierdo Elena JM, Novoa Valentín NM, Rivas de Andrés JJ, Royo Crespo Í, Salvatierra Velázquez Á, Seijo Maceiras LM, Solano Reina S, Aguiar Bujanda D, Avila Martínez RJ, de Granda Orive JI, de Higes Martinez E, Diaz-Hellín Gude V, Embún Flor R, Freixinet Gilart JL, García Jiménez MD, Hermoso Alarza F, Hernández Sarmiento S, Honguero Martínez AF, Jimenez Ruiz CA, López Sanz I, Mariscal de Alba A, Martínez Vallina P, Menal Muñoz P, Mezquita Pérez L, Olmedo García ME, Rombolá CA, San Miguel Arregui I, de Valle Somiedo Gutiérrez M, Triviño Ramírez AI, Trujillo Reyes JC, Vallejo C, Vaquero Lozano P, Varela Simó G, Zulueta JJ.

Arch Bronconeumol. 2016 Jul;52(7):378-88. doi: 10.1016/j.arbres.2016.02.016. Epub 2016 May 27. English, Spanish.

21.

Assessment of indeterminate pulmonary nodules detected in lung cancer screening: Diagnostic accuracy of FDG PET/CT.

Garcia-Velloso MJ, Bastarrika G, de-Torres JP, Lozano MD, Sanchez-Salcedo P, Sancho L, Nuñez-Cordoba JM, Campo A, Alcaide AB, Torre W, Richter JA, Zulueta JJ.

Lung Cancer. 2016 Jul;97:81-6. doi: 10.1016/j.lungcan.2016.04.025. Epub 2016 May 2.

PMID:
27237032
22.

The neutrophil to lymphocyte and platelet to lymphocyte ratios as biomarkers for lung cancer development.

Sanchez-Salcedo P, de-Torres JP, Martinez-Urbistondo D, Gonzalez-Gutierrez J, Berto J, Campo A, Alcaide AB, Zulueta JJ.

Lung Cancer. 2016 Jul;97:28-34. doi: 10.1016/j.lungcan.2016.04.010. Epub 2016 Apr 16.

PMID:
27237024
23.

Lung cancer screening in patients with chronic obstructive pulmonary disease.

Gonzalez J, Marín M, Sánchez-Salcedo P, Zulueta JJ.

Ann Transl Med. 2016 Apr;4(8):160. doi: 10.21037/atm.2016.03.57. Review.

24.

Is COPD a Progressive Disease? A Long Term Bode Cohort Observation.

de-Torres JP, Marín JM, Pinto-Plata V, Divo M, Sanchez-Salcedo P, Zagaceta J, Zulueta JJ, Berto J, Cabrera C, Celli BR, Casanova C.

PLoS One. 2016 Apr 21;11(4):e0151856. doi: 10.1371/journal.pone.0151856. eCollection 2016.

25.

Lung cancer in chronic obstructive pulmonary disease patients, it is not just the cigarette smoke.

Sanchez-Salcedo P, Zulueta JJ.

Curr Opin Pulm Med. 2016 Jul;22(4):344-9. doi: 10.1097/MCP.0000000000000283. Review.

PMID:
27077725
26.

Identification of COPD Patients at High Risk for Lung Cancer Mortality Using the COPD-LUCSS-DLCO.

de-Torres JP, Marín JM, Casanova C, Pinto-Plata V, Divo M, Cote C, Celli BR, Zulueta JJ.

Chest. 2016 Apr;149(4):936-42. doi: 10.1378/chest.15-1868. Epub 2016 Jan 12.

PMID:
26513409
27.

Effects of Small-Sided Games vs. Interval Training in Aerobic Fitness and Physical Enjoyment in Young Elite Soccer Players.

Los Arcos A, Vázquez JS, Martín J, Lerga J, Sánchez F, Villagra F, Zulueta JJ.

PLoS One. 2015 Sep 2;10(9):e0137224. doi: 10.1371/journal.pone.0137224. eCollection 2015.

28.

Emphysema and Lung Cancer. More Than a Coincidence.

Zulueta JJ.

Ann Am Thorac Soc. 2015 Aug;12(8):1120-1. doi: 10.1513/AnnalsATS.201506-360ED. No abstract available.

PMID:
26317271
29.

COPD comorbidities network.

Divo MJ, Casanova C, Marin JM, Pinto-Plata VM, de-Torres JP, Zulueta JJ, Cabrera C, Zagaceta J, Sanchez-Salcedo P, Berto J, Davila RB, Alcaide AB, Cote C, Celli BR; BODE Collaborative Group.

Eur Respir J. 2015 Sep;46(3):640-50. doi: 10.1183/09031936.00171614. Epub 2015 Jul 9.

30.

Lung Cancer Screening: The Balance between Harm and Benefit.

Zulueta JJ, de-Torres JP.

Am J Respir Crit Care Med. 2015 May 15;191(10):1209. doi: 10.1164/rccm.201502-0345LE. No abstract available.

PMID:
25978578
31.

A randomised trial of lung sealant versus medical therapy for advanced emphysema.

Come CE, Kramer MR, Dransfield MT, Abu-Hijleh M, Berkowitz D, Bezzi M, Bhatt SP, Boyd MB, Cases E, Chen AC, Cooper CB, Flandes J, Gildea T, Gotfried M, Hogarth DK, Kolandaivelu K, Leeds W, Liesching T, Marchetti N, Marquette C, Mularski RA, Pinto-Plata VM, Pritchett MA, Rafeq S, Rubio ER, Slebos DJ, Stratakos G, Sy A, Tsai LW, Wahidi M, Walsh J, Wells JM, Whitten PE, Yusen R, Zulueta JJ, Criner GJ, Washko GR.

Eur Respir J. 2015 Sep;46(3):651-62. doi: 10.1183/09031936.00205614. Epub 2015 Apr 2.

32.

Elevated levels of the complement activation product C4d in bronchial fluids for the diagnosis of lung cancer.

Ajona D, Razquin C, Pastor MD, Pajares MJ, Garcia J, Cardenal F, Fleischhacker M, Lozano MD, Zulueta JJ, Schmidt B, Nadal E, Paz-Ares L, Montuenga LM, Pio R.

PLoS One. 2015 Mar 23;10(3):e0119878. doi: 10.1371/journal.pone.0119878. eCollection 2015.

33.

CT screening for lung cancer: Importance of emphysema for never smokers and smokers.

Henschke CI, Yip R, Boffetta P, Markowitz S, Miller A, Hanaoka T, Wu N, Zulueta JJ, Yankelevitz DF; I-ELCAP Investigators.

Lung Cancer. 2015 Apr;88(1):42-7. doi: 10.1016/j.lungcan.2015.01.014. Epub 2015 Feb 4.

PMID:
25698134
34.

Improving selection criteria for lung cancer screening. The potential role of emphysema.

Sanchez-Salcedo P, Wilson DO, de-Torres JP, Weissfeld JL, Berto J, Campo A, Alcaide AB, Pueyo J, Bastarrika G, Seijo LM, Pajares MJ, Pio R, Montuenga LM, Zulueta JJ.

Am J Respir Crit Care Med. 2015 Apr 15;191(8):924-31. doi: 10.1164/rccm.201410-1848OC.

35.

Lung cancer screening: fourteen year experience of the Pamplona early detection program (P-IELCAP).

Sanchez-Salcedo P, Berto J, de-Torres JP, Campo A, Alcaide AB, Bastarrika G, Pueyo JC, Villanueva A, Echeveste JI, Lozano MD, García-Velloso MJ, Seijo LM, García J, Torre W, Pajares MJ, Pío R, Montuenga LM, Zulueta JJ.

Arch Bronconeumol. 2015 Apr;51(4):169-76. doi: 10.1016/j.arbres.2014.09.019. Epub 2015 Jan 29. English, Spanish.

36.

Lung cancer in patients with chronic obstructive pulmonary disease. Development and validation of the COPD Lung Cancer Screening Score.

de-Torres JP, Wilson DO, Sanchez-Salcedo P, Weissfeld JL, Berto J, Campo A, Alcaide AB, García-Granero M, Celli BR, Zulueta JJ.

Am J Respir Crit Care Med. 2015 Feb 1;191(3):285-91. doi: 10.1164/rccm.201407-1210OC.

37.

[Overdiagnosis in cancer screening].

Cervera Deval J, Sentís Crivillé M, Zulueta JJ.

Radiologia. 2015 May-Jun;57(3):188-92. doi: 10.1016/j.rx.2014.06.007. Epub 2014 Aug 29. Spanish.

38.

Role of [¹⁸F]FDG PET in prediction of KRAS and EGFR mutation status in patients with advanced non-small-cell lung cancer.

Caicedo C, Garcia-Velloso MJ, Lozano MD, Labiano T, Vigil Diaz C, Lopez-Picazo JM, Gurpide A, Zulueta JJ, Richter Echevarria JA, Perez Gracia JL.

Eur J Nucl Med Mol Imaging. 2014 Nov;41(11):2058-65. doi: 10.1007/s00259-014-2833-4. Epub 2014 Jul 3. Erratum in: Eur J Nucl Med Mol Imaging. 2014 Nov;41(11):2164. Zulueta, Javier [corrected to Zulueta, Javier J].

PMID:
24990403
39.

Prognostic evaluation of COPD patients: GOLD 2011 versus BODE and the COPD comorbidity index COTE.

de Torres JP, Casanova C, Marín JM, Pinto-Plata V, Divo M, Zulueta JJ, Berto J, Zagaceta J, Sanchez-Salcedo P, Cabrera C, Carrizo S, Cote C, Celli BR.

Thorax. 2014 Sep;69(9):799-804. doi: 10.1136/thoraxjnl-2014-205770. Epub 2014 Jun 26.

PMID:
24969641
40.

Variations in molecular profile in NSCLC can be analyzed using cytological samples: development of EGFR resistance mutations and coexistence of ALK-EML4 translocation in an EGFR-sensitive patient.

Lozano MD, Labiano T, Zudaire I, Subtil JC, Gúrpide A, Echeveste JI, Zulueta JJ, Martín-Algarra S, Pérez-Gracia JL.

Int J Surg Pathol. 2015 Apr;23(2):111-5. doi: 10.1177/1066896914539551. Epub 2014 Jun 17.

PMID:
24942894
41.

Disease progression in young patients with COPD: rethinking the Fletcher and Peto model.

Sanchez-Salcedo P, Divo M, Casanova C, Pinto-Plata V, de-Torres JP, Cote C, Cabrera C, Zagaceta J, Rodriguez-Roisin R, Zulueta JJ, Marin JM, Celli B.

Eur Respir J. 2014 Aug;44(2):324-31. doi: 10.1183/09031936.00208613. Epub 2014 Apr 2.

42.

Response to "Exploring the impact of screening with low-dose CT on lung cancer mortality in mild to moderate COPD patients".

de-Torres JP, Zulueta JJ.

Respir Med. 2014 May;108(5):815. doi: 10.1016/j.rmed.2014.01.011. Epub 2014 Feb 15. No abstract available.

43.

Endobronchial valves for advanced emphysema: an endobronchial follow-up.

Salcedo PS, Seijo LM, Zulueta JJ.

J Bronchology Interv Pulmonol. 2014 Jan;21(1):47-50. doi: 10.1097/LBR.0000000000000035.

PMID:
24419186
44.

Investigation of complement activation product c4d as a diagnostic and prognostic biomarker for lung cancer.

Ajona D, Pajares MJ, Corrales L, Perez-Gracia JL, Agorreta J, Lozano MD, Torre W, Massion PP, de-Torres JP, Jantus-Lewintre E, Camps C, Zulueta JJ, Montuenga LM, Pio R.

J Natl Cancer Inst. 2013 Sep 18;105(18):1385-93. doi: 10.1093/jnci/djt205. Epub 2013 Aug 12.

45.

Epicardial adipose tissue in patients with chronic obstructive pulmonary disease.

Zagaceta J, Zulueta JJ, Bastarrika G, Colina I, Alcaide AB, Campo A, Celli BR, de Torres JP.

PLoS One. 2013 Jun 6;8(6):e65593. doi: 10.1371/journal.pone.0065593. Print 2013.

47.

Smokers with CT detected emphysema and no airway obstruction have decreased plasma levels of EGF, IL-15, IL-8 and IL-1ra.

de-Torres JP, Blanco D, Alcaide AB, Seijo LM, Bastarrika G, Pajares MJ, Muñoz-Barrutia A, Ortiz-de-Solorzano C, Pio R, Campo A, Montes U, Segura V, Pueyo J, Montuenga LM, Zulueta JJ.

PLoS One. 2013;8(4):e60260. doi: 10.1371/journal.pone.0060260. Epub 2013 Apr 5.

48.

Exploring the impact of screening with low-dose CT on lung cancer mortality in mild to moderate COPD patients: a pilot study.

de-Torres JP, Casanova C, Marín JM, Zagaceta J, Alcaide AB, Seijo LM, Campo A, Carrizo S, Montes U, Cordoba-Lanus E, Baz-Dávila R, Aguirre-Jaime A, Celli BR, Zulueta JJ.

Respir Med. 2013 May;107(5):702-7. doi: 10.1016/j.rmed.2013.01.013. Epub 2013 Mar 7.

49.

Modified technique for obtaining mediastinal samples with endobronchial ultrasound-guided transbronchial needle aspiration: results from a prospective observational study.

Rodríguez F, Seijo LM, Sánchez PA, Zulueta JJ.

Arch Bronconeumol. 2013 Apr;49(4):135-9. doi: 10.1016/j.arbres.2012.10.006. Epub 2012 Dec 20. English, Spanish.

50.

Lung cancer associated with cystic airspaces.

Farooqi AO, Cham M, Zhang L, Beasley MB, Austin JH, Miller A, Zulueta JJ, Roberts H, Enser C, Kao SJ, Thorsen MK, Smith JP, Libby DM, Yip R, Yankelevitz DF, Henschke CI; International Early Lung Cancer Action Program Investigators.

AJR Am J Roentgenol. 2012 Oct;199(4):781-6.

PMID:
22997368

Supplemental Content

Loading ...
Support Center